
浏览全部资源
扫码关注微信
1.青海大学药学院,西宁 810016
2.青海省人民医院药学部,西宁 810007
3.青海省人民医院骨科,西宁 810007
硕士研究生。研究方向:临床药学。E-mail:1850079584@qq.com
副主任药师,硕士生导师。研究方向:临床药学。 E-mail:wxh_8284@163.com
收稿:2025-07-23,
修回:2025-12-09,
录用:2025-12-10,
纸质出版:2026-01-15
移动端阅览
牟妍红,吴雪花,李永芳,等.脊柱结核患者血浆中3种抗结核药物浓度测定方法的建立及临床应用 [J].中国药房,2026,37(01):72-76.
MOU Yanhong,WU Xuehua,LI Yongfang,et al.Establishment and clinical application of a method for the determination of three anti-tuberculosis drugs concentrations in plasma of patients with spinal tuberculosis[J].ZHONGGUO YAOFANG,2026,37(01):72-76.
牟妍红,吴雪花,李永芳,等.脊柱结核患者血浆中3种抗结核药物浓度测定方法的建立及临床应用 [J].中国药房,2026,37(01):72-76. DOI: 10.6039/j.issn.1001-0408.2026.01.13.
MOU Yanhong,WU Xuehua,LI Yongfang,et al.Establishment and clinical application of a method for the determination of three anti-tuberculosis drugs concentrations in plasma of patients with spinal tuberculosis[J].ZHONGGUO YAOFANG,2026,37(01):72-76. DOI: 10.6039/j.issn.1001-0408.2026.01.13.
目的
2
建立同时测定脊柱结核患者血浆中3种抗结核药物浓度的方法,并将该法应用于临床。
方法
2
以苯海拉明为内标,采用液相色谱-串联质谱(LC-MS/MS)技术建立同时测定脊柱结核患者血浆中异烟肼、利福平和吡嗪酰胺浓度的方法。以Chemalink CM-C
18
T为色谱柱,0.1%甲酸-甲醇溶液为流动相进行梯度洗脱,流速为0.4 mL/min,进样体积为2 μL;采用电喷雾离子源在正离子模式下进行多反应监测,用于定量分析的离子对分别为
m
/
z
138.0→121.0(异烟肼)、
m
/
z
823.3→791.3(利福平)、
m
/
z
124.1→79.0(吡嗪酰胺)、
m
/
z
256.0→167.0(苯海拉明)。选择2023年1月-2025年6月在青海省人民医院住院的53例脊柱结核患者,采用上述方法测定患者血浆中异烟肼、利福平和吡嗪酰胺浓度。
结果
2
异烟肼、利福平和吡嗪酰胺的线性范围分别为0.5~16、
2~64、2.5~80 μg/mL(
r
不低于0.998 7),准确度为90.20%~108.64%(
n
=5),日内精密度的RSD均小于6.63%(
n
=5),日间精密度的RSD均小于8.42%(
n
=3),基质效应为88.60%~115.41%(
n
=5),稳定性试验的相对偏差均在±15%范围内,残留效应对测定无干扰。临床应用结果显示,脊柱结核患者体内异烟肼、利福平、吡嗪酰胺的平均血药浓度分别为(3.62±2.80)、(8.55±4.57)、(20.12±6.56)μg/mL,血药浓度低于有效峰浓度的发生率分别为49.06%、58.49%、60.38%。
结论
2
本研究所建立的方法快速准确、稳定性好,可用于临床监测脊柱结核患者血浆中异烟肼、利福平和吡嗪酰胺的浓度。
OBJECTIVE
2
To establish a method for simultaneously determining three anti-tuberculosis drugs in the plasma of patients with spinal tuberculosis and apply it in clinical practice.
METHODS
2
LC-MS/MS method was established for the quantitative determination of the concentrations of isoniazid, rifampicin and pyrazinamide in the plasma of patients with spinal tuberculosis, using diphenhydramine as the internal standard. The determination was carried out using Chemalink CM-C
18
T column, with mobile phase consisting of 0.1% formic acid-methanol solution (gradient elution), at the flow rate of 0.4 mL/min and an injection volume of 2 μL. Multiple reaction monitoring was conducted using an electrospray ionization source in positive ion mode. The ion pairs used for quantitative analysis were
m
/
z
138.0→121.0 (for isoniazid),
m
/
z
823.3→791.3 (for rifampicin),
m
/
z
124.1→79.0 (for pyrazinamide), and
m
/
z
256.0→167.0 (for diphenhydramine). Fifty-three patients diagnosed with spinal tuberculosis in Qinghai Provincial People’s Hospital from January 2023 to June 2025 were selected, and the plasma concentrations of isoniazid, rifampicin and pyrazinamide in these patients were measured using the above method.
RESULTS
2
The linear ranges for isoniazid, rifampicin and pyrazinamide were 0.5-16, 2-64
, and 2.5-80 μg/mL, respectively (
r
≥0.998 7). The accuracy ranged from 90.20% to 108.64% (
n
=5). RSDs for intra-day precision were all less than 6.63% (
n
=5), while those for inter-day precision were all less than 8.42% (
n
=3). The matrix effects ranged from 88.60% to 115.41% (
n
=5). The relative deviations in the stability tests were all within the ±15% range, and the carry-over effect did not interfere with the determination. The results of clinical application showed that the mean plasma drug concentrations of isoniazid, rifampicin and pyrazinamide in patients with spinal tuberculosis were (3.62±2.80), (8.55±4.57), and (20.12±6.56) μg/mL, respectively. The incidences of plasma drug concentrations falling below the effective peak concentrations were 49.06%, 58.49% and 60.38%, respectively.
CONCLUSIONS
2
The method established in this study is rapid, accurate, and demonstrates good stability, making it suitable for clinical monitoring of the plasma concentrations of isoniazid, rifampicin and pyrazinamide in patients with spinal tuberculosis.
World Health Organization . Global tuberculosis report 2024 [EB/OL ] .[ 2025-06-23 ] . https://publichealthupdate.com/global-tuberculosis-report-2024/ https://publichealthupdate.com/global-tuberculosis-report-2024/ .
宋向伟 , 马犇 , 安永博 , 等 . 脊柱结核的化疗现状 [J ] . 实用药物与临床 , 2023 , 26 ( 7 ): 669 - 672 .
KOTIL K , ALAN M S , BILGE T . Medical management of Pott disease in the thoracic and lumbar spine:a prospective clinical study [J ] . J Neurosurg Spine , 2007 , 6 ( 3 ): 222 - 228 .
GARG D , GOYAL V . Spinal tuberculosis treatment:an enduring bone of contention [J ] . Ann Indian Acad Neurol , 2020 , 23 ( 4 ): 441 - 448 .
FAGE D , BRILLEMAN R , DEPREZ G , et al . Development,validation and clinical use of a LC-MS/MS method for the simultaneous determination of the nine main antituberculosis drugs in human plasma [J ] . J Pharm Biomed Anal , 2022 , 215 : 114776 .
国家药典委员会 . 中华人民共和国药典:四部 [M ] . 2020年版 . 北京 : 中国医药科技出版社 , 2020 : 466 - 472 .
陆宇 , 朱慧 . 抗结核药治疗药物监测临床应用专家共识 [J ] . 中国防痨杂志 , 2021 , 43 ( 9 ): 867 - 873 .
HERNÁNDEZ-GONZÁLEZ O , ZARAZÚA S , VEYTIA-BUCHELI J I , et al . Quantification of pyrazinamide,isoniazid,acetyl-isoniazid,and rifampicin by a high-performance liquid chromatography method in human plasma from patients with tuberculosis [J ] . J Sep Sci , 2021 , 44 ( 2 ): 521 - 529 .
梁英杰 , 亓琳 , 韩水 , 等 . HPLC-MS/MS法同时测定人血清中4种一线抗结核药物浓度及其临床应用 [J ] . 南开大学学报(自然科学版) , 2020 , 53 ( 3 ): 49 - 57 .
张宇 , 刘小玉 , 徐风 , 等 . UPLC-MS/MS法测定淋巴结结核患者血浆和组织异烟肼浓度的临床价值研究 [J ] . 中国药师 , 2023 , 26 ( 11 ): 311 - 318 .
丁巧燕 , 张欢 , 马丽华 , 等 . 德拉马尼血药浓度测定方法的建立及应用 [J ] . 中国药房 , 2022 , 33 ( 24 ): 3029 - 3033 .
吕锦绣 , 颜楠 , 徐文俊 , 等 . 7种抗肿瘤药物血药浓度测定方法建立及临床应用 [J ] . 中国药房 , 2025 , 36 ( 4 ): 475 - 481 .
JAIN M , PRADHAN S S , TRIPATHY S K , et al . Association between nutritional scores and multilevel vertebral involvement in tubercular spine:a retrospective cohort study [J ] . Eur Spine J , 2024 , 33 ( 9 ): 3409 - 3419 .
0
浏览量
11
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621